Century Therapeutics (NASDAQ:IPSC) Stock Rating Cut to Sell at Wall Street Zen

Century Therapeutics (NASDAQ:IPSC – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday, Wall Street Zen reports.

Separately, Weiss Ratings lowered shares of Century Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, November 13th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.75.

Read Our Latest Research Report on IPSC

Century Therapeutics Stock Down 11.7%

Century Therapeutics stock opened at $1.17 on Friday. Century Therapeutics has a twelve month low of $0.46 and a twelve month high of $3.04. The stock has a market capitalization of $211.56 million, a PE ratio of -1.82 and a beta of 1.78. The company has a 50 day moving average of $1.58 and a 200-day moving average of $2.05.

Century Therapeutics (NASDAQ:IPSC – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. Equities analysts anticipate that Century Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp bought a new stake in Century Therapeutics during the first quarter valued at $29,000. State of Wyoming bought a new position in shares of Century Therapeutics in the 2nd quarter worth about $82,000. The Manufacturers Life Insurance Company bought a new position in shares of Century Therapeutics in the 2nd quarter worth about $85,000. Legal & General Group Plc bought a new position in shares of Century Therapeutics in the 2nd quarter worth about $108,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Century Therapeutics in the 1st quarter valued at about $108,000. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

(Get Free Report)

Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence.

See Also

Analyst Recommendations for Century Therapeutics (NASDAQ:IPSC)

Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.